EU CHMP recommends approval of Empliciti (elotuzumab) plus lenalidomide and dexamethasone for multiple myeloma- BMS
The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Empliciti (elotuzumab), from BMS, intended for the treatment of multiple myeloma. Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. It is proposed that Empliciti therapy should be initiated and supervised by physicians experienced in the treatment of multiple myeloma.
The CHMP’s recommendation is based on a randomised, open-label Phase III study evaluating Empliciti in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with relapsed or refractory multiple myeloma. The trial enrolled 646 patients whose multiple myeloma came back after, or did not respond to, previous treatment. In patients also taking Empliciti, the disease progressed more slowly (difference in medians of 4.2 months) than in patients taking only lenalidomide and dexamethasone. In addition, 78.5% of patients taking Empliciti with lenalidomide and dexamethasone saw a complete or partial shrinkage of their tumours compared to 65.5% in those only taking lenalidomide and dexamethasone.
Comment: Darzalex (daratumumab) from Janssen Biotech, approved earlier this month, is the only other FDA-approved monoclonal antibody for the treatment of patients with multiple myeloma. Other recently approved drugs for multiple myeloma are Pomalyst (pomalidomide) from Celgene and Darzalex (daratumumab) from Janssen Biotech.The potential market leader may be Kyprolis (carfilzomib) from Amgen .
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)